Drug Trial Radar · NCT07604285
A Phase 1/2 Study of Safety and Tolerability of MT-125 With Chemoradiation in Patients With Newly Diagnosed MGMT Methylated Glioblastoma
Last checked: Nov 19, 2026Latest source record: May 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
36
Planned (sponsor's estimate)
Start
Jul 2026
Primary completion
Mar 2027
Study completion Mar 2027
Sponsor
- Lead sponsor
- Myosin Therapeutics Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Mayo Clinic
- First posted
- May 22, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 1, single-arm MT-125 dose escalation study followed by a Phase 2, randomized parallel design dose expansion phase, to determine the safety and tolerability of MT-125 administered 5 consecutive days a week with 2 days off for the 6 weeks of outpatient treatment of Radiotherapy (RT) plus TMZ. Participants with newly diagnosed histologically or molecularly confirmed IDH wild type and MGMT methylated GBM will be eligible to enroll. The dose-limiting toxicity (DLT) observation window will be 6 weeks, starting with the first dose of MT-125 administration and chemoradiation. A Bayesian Optimal Interval (BOIN) adaptive trial design will be used to efficiently evaluate up to four dose levels. Secondary endpoints for this Phase 1/2 study will include determination of the MTD, the systemic PK of MT-125, and the RP2D of MT-125. Once the MTD is defined, additional participants will be enrolled as part of an expansion cohort, with a randomized parallel design, which will include up to 2 dose levels which are expected to be MTD and one dose below the MTD. Up to 36 participants will be enrolled in the study (up to 24 participants in the dose escalation phase and up to a total of 12 participants maximum per dose level for the two expansion cohorts).
Conditions
- Glioblastoma
Interventions
MT-125Drug
This is an investigational new drug under IND 170975.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose Limiting Toxicity MeasurementTime frame: Day 1 through 6 weeks of treatment
- Incidence and Severity of AEsTime frame: Day 1 through 6 weeks of treatment
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Mayo Clinic Hospital
Phoenix, Arizona
Mayo Clinic Hospital
Jacksonville, Florida
Mayo Clinic Hospital
Rochester, Minnesota
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.